The international, multicenter, prospective, double-blind randomized controlled EXCLAIM trial has been previously reported. 3 Patients aged over 40 years, hospitalized for an acute medical illness with recent reduced mobility for a maximum of 3 days and an anticipated mobility reduction for a further 3 days, were eligible.
A cute ischemic stroke patients are at high risk of developing deep-vein thrombosis (DVT) and pulmonary embolism (PE), which are the major causes of mortality and morbidity in these patients. 1, 2 Some consensus guidelines recommend venous thromboembolism (VTE) prophylaxis with unfractionated heparin or low-molecular-weight heparins in acute stroke patients with restricted mobility, although there is no guidance on prophylaxis duration. 2 The EXCLAIM (EXtended CLinical prophylaxis in Acutely Ill Medical patients) study reported that extended-duration enoxaparin (for a further 28 days after standard 10-day enoxaparin prophylaxis) reduced the risk of VTE but increased major bleeding complications. Women, older patients (>75 years), and sedentary patients experienced reduction in risk of VTE. 3 This subanalysis assessed the risk of VTE and bleeding with extended-duration enoxaparin prophylaxis in patients with acute ischemic stroke.
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DVT, symptomatic PE, or fatal PE, during the double-blind period of extended prophylaxis. The primary safety end point was the incidence of major hemorrhagic complications during, and up to 48 h after, the double-blind treatment period.
Statistical Analyses
VTE and bleeding events were compared between groups using chisquare and Fisher exact tests. Univariate and multivariate logistic regression models were employed to look at the association between VTE and risk factors. Cox proportional hazard models were used to analyze the relationship between treatment and all-cause mortality.
Results
A total of 389 ischemic stroke patients were identified: in the safety population, 198 patients received extended-duration enoxaparin and 191 received placebo; in the efficacy population, 166 patients received extended-duration enoxaparin and 150 received placebo (Supplementary Appendix, Figure 1 ). The mean age was 68.1 years (66.9 years in the enoxaparin group; 69.4 years in the placebo group).
In ischemic stroke patients, extended-duration prophylaxis with enoxaparin was associated with a reduction in the incidence of VTE at 1 month compared with placebo (2.4% versus 8.0%, respectively, Table 1 ). No cases of symptomatic VTE were observed in patients who received extendedduration enoxaparin during the double-blind phase versus 2 events (both symptomatic DVT) in those who received placebo (Table 1 ). There was one fatal PE in the placebo group.
Major bleeding occurred in 1.5% (3/198) of patients who received extended-duration prophylaxis versus none in the placebo (Table 1 ). There was one fatal intracranial bleeding event and a trend toward increased rates of total bleeding in patients receiving extended-duration enoxaparin (Table 1) .
Prior VTE and obesity were associated with an increased rate of VTE (Supplementary Appendix, Table 1 ). In the multivariate analysis, only prior VTE was an independent predictor of VTE (P=0.0088). The multivariate model indicated that the adjusted odds ratio for treatment effect was 0.32, versus 0.28 unadjusted, suggesting that any imbalance in well-recognized VTE risk factors between the treatment groups has a very limited impact on treatment effect.
Discussion
This subanalysis showed that extended-duration prophylaxis with enoxaparin reduced the VTE incidence and increased major bleeding in the subgroup of patients with ischemic stroke in the EXCLAIM study. Without VTE prophylaxis, ischemic stroke patients remain at high risk of VTE for at least 1 month after the index stroke.
Our findings support earlier data that the risk of VTE is reduced when stroke patients receive extended-duration VTE prophylaxis. [4] [5] [6] Stroke patients often experience long periods of immobility, a known risk factor for VTE. 4, 6 Autopsy evidence suggests that while fatal PEs are rare in the first week after a stroke, they are most frequent, and become the main cause of mortality, in the second-to-fourth weeks after the stroke. 7, 8 A previous study reported that prolonged thromboprophylaxis during stroke rehabilitation may reduce the incidence of VTE in stroke patients. 5 Prior VTE was predictive of post-stroke VTE in a multivariate analysis. This subanalysis suggests that extended thromboprophylaxis is associated with a reduced risk of VTE and an increase in major bleeding in ischemic stroke patients. The CI, confidence interval; DVT, deep-vein thrombosis; VTE, venous thromboembolism. *Two patients in the extended-duration enoxaparin group and 3 patients in the placebo group had a recurrent ischemic stroke during the double-blind period.
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question on the optimal duration of VTE prevention in this patient group remains open, calling for additional studies in this setting.
Conclusions
Ischemic stroke patients with reduced mobility remain at high risk for VTE for at least 1 month following the index stroke.
In the subgroup of patients with ischemic stroke, extendedduration prophylaxis with enoxaparin was associated with a reduction in the incidence of VTE and an increase in major bleeding.
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Investigators
SUPPLEMENTAL MATERIAL
Interim analysis
After a planned interim analysis, eligibility criteria were amended for patients with level 2 immobility (total bed rest or sedentary with bathroom privileges) to include only those with additional VTE risk factors: age >75 years, a history of VTE, or active or prior cancer.
For further reference please see: 
Assessment of outcomes
The primary efficacy endpoint was assessed in the total efficacy population that included all randomized patients who received at least one dose of study medication during the double-blind treatment period, had a confirmed VTE within 7 days after cessation of study treatment, or had at least one interpretable ultrasound evaluation during the double-blind treatment period (day 28±4). Bleeding parameters were assessed in the total safety population, which included the subpopulations of all randomized ischemic stroke patients and all acutely medically ill non-stroke patients who received at least one dose of study medication during the double-blind period.
Results -bleeding during open-label treatment
During the open-label phase of the study, 29/454 (6.4%) patients experienced bleeding, of which 6 (1.3%) was adjudicated as major bleeding and 23 (5.1%) were classified as minor bleeds.
Study limitations
There are limitations to this subanalysis. The small sample size and low event rates may reduce the statistical power of comparisons between treatment groups. Intracranial bleeding was not assessed by systematic computerized tomography scans. Stroke severity was measured by the level of resulting immobility instead of using specific scale scores such as the National Institute of Health Stroke Scale or the modified Rankin scale scores. This may limit the generalizability of our findings and restricts our ability to comment on the comparative benefits of extendedduration enoxaparin thromboprophylaxis in patients with severe, compared with less severe, ischemic stroke.
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